Cover Image
市場調查報告書

EVP-6124(精神分裂症治療藥):市場預測與分析

EVP-6124 (Schizophrenia) - Forecast and Market Analysis to 2022

出版商 GlobalData 商品編碼 299187
出版日期 內容資訊 英文 58 Pages
訂單完成後即時交付
價格
Back to Top
EVP-6124(精神分裂症治療藥):市場預測與分析 EVP-6124 (Schizophrenia) - Forecast and Market Analysis to 2022
出版日期: 2014年02月28日 內容資訊: 英文 58 Pages
簡介

EVP-6124是小分子型a7尼古丁性乙醯膽鹼受體(nAChR)受體激動劑,現在由EnVivo和三菱田邊製藥共同開發中。目前正在研究將a7 nAChR的刺激作用應用在許多神經障礙(老年癡呆症,尼古丁依賴症等)治療法上。這是因為這個刺激作用具有緩和目標的腦神經炎症障礙途徑的可能性,(Tracey, 2007)便是這個研究的結果。EVP-6124是以3-(1-methylpyrrolidin-2-yl)吡啶知名的口服藥法,由於其強力的親油性而可滲入中樞神經。這個藥劑可作為乙醯膽鹼(ACh)受體的共同受體激動劑,此外因為增加了敏感性,而可使微量的ACh也能維持一般認知機能。由於EVP-6124はa7有選擇性,對a4ß2亞基不起反應,這表示它可說毫無成癮性。

本報告提供精神分裂症治療藥之一──Bitopertin的全球市場相關分析,提供精神分裂症概要和治療方法,Zicronapine的商品資訊(特色·功效·安全性等)和競爭力,競爭的企業·藥品概要,市場機會及未滿足需求,臨床實驗的進展,全球主要國家的市場販售額預測(今後10年分)等調查,並將結果概述為以下內容。

第1章 目錄

第2章 簡介

第3章 疾病概要

  • 病因與病情
    • 病因
    • 病理
  • 症狀

第4章 疾病的管理

  • 診斷
    • 主觀的評估
    • 疾病的分類
  • 治療方法概要
    • 精神分裂症相關的急性激越症狀
    • 精神分裂症的維持療法

第5章 競爭企業的評估

  • 概要
  • 競爭企業的策略性評估

第6章 市場機會及未滿足需求

  • 未滿足需求概要
    • 一般的認知度
    • 早期診斷·治療
    • 長效型·最尖端的藥物遞輸系統
    • 有效管理負面症狀·認知症狀
  • 差距分析
    • 長效型的藥物遞輸
    • 負面症狀·認知症狀的治療

第7章 開發平台評估

  • 概要
  • 初期階段的開發中產品評估
  • 新的治療方法
    • 負面症狀
    • 認知症狀
  • 長效型的藥物遞輸
  • 技術趨勢分析
  • 處於臨床實驗階段的主要醫藥品

第8章 關於EVP-6124

  • 概要
  • 功效
  • 安全性
    • 給藥·劑型方法
    • 臨床方面的潛在定位
    • 商業方面的潛在定位
    • 價格設定和醫療費給付
  • SWOT分析
  • 預測

第9章 附錄

圖表一覽

目錄
Product Code: GDHC370DFR

Schizophrenia is a persistent long-term brain disorder that causes severe, debilitating psychotic episodes. Its core symptoms, auditory or visual hallucinations, are often accompanied by fixed, false, and often paranoid beliefs, called delusions. These two features are often combined with learning and cognitive deficits. WHO experts have estimated that roughly 24 million people are affected by schizophrenia worldwide. While the arrival of atypical antipsychotics has greatly expanded pharmacologic treatment options over the past two decades, the current drug market does not treat the negative and cognitive symptoms that are associated with the disease. GlobalData expects that the growing popularity of long-acting injectable (LAI) antipsychotics, along with the arrival of novel treatments that achieve higher efficacy in negative- and cognitive-predominant patients, will serve to stimulate growth in the marketplace over the forecast period. Country-specific treatment recommendations and policy implementation will be an essential metric for determining future mental health services in the 7MM.

EVP-6124 is a small-molecule a7 nicotinic acetylcholine receptor (nAChR) agonist in co-development by EnVivo and Mitsubishi Tanabe. a7 nAChR stimulation is being researched as a therapy for several neurological conditions, including larger indications such as Alzheimer's disease and nicotine dependence, following the observation that the target may modulate neuroinflammatory pathways in the brain (Tracey, 2007). Also known as 3-(1-methylpyrrolidin-2-yl) pyridine, EVP-6124 is an oral medication that penetrates the CNS easily due to its strong lipophilicity. It acts as a co-agonist and sensitizes the ACh receptors so that lesser amounts of ACh can preserve normal cognitive functioning. EVP-6124 is a7-selective and does not activate the a4ß2 subunit, meaning it is non-addictive.

Scope

  • Overview of Schizophrenia, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on EVP-6124 including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for EVP-6124 for the top seven countries from 2012 to 2022.
  • Sales information covered for the US, France, Germany, Italy, Spain, the UK and Japan

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of the competition by understanding the changing competitive landscape for Schizophrenia
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of EVP-6124 performance
  • Obtain sales forecast for EVP-6124 from 2012-2022 in the top seven countries (the US, France, Germany, Italy, Spain, the UK and Japan)

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports
  • 2.3. Upcoming Reports

3. Disease Overview

  • 3.1. Etiology and Pathophysiology
    • 3.1.1. Etiology
    • 3.1.2. Pathophysiology
  • 3.2. Symptoms

4. Disease Management

  • 4.1. Diagnosis
    • 4.1.1. Subjective Assessments
    • 4.1.2. Disease Subtypes
  • 4.2. Treatment Overview
    • 4.2.1. Treatment of Acute Agitation Associated with Schizophrenia
    • 4.2.2. Maintenance Treatment of Schizophrenia

5. Competitive Assessment

  • 5.1. Overview
  • 5.2. Strategic Competitor Assessment

6. Opportunity and Unmet Need

  • 6.1. Unmet Needs Overview
    • 6.1.1. Public Awareness
    • 6.1.2. Early Diagnosis and Treatment
    • 6.1.3. Long-Acting and Advanced Drug Delivery Systems
    • 6.1.4. Effective Management of Negative and Cognitive Symptom Domains
  • 6.2. Gap Analysis
    • 6.2.1. Long-Acting Drug Delivery
    • 6.2.2. Treatment of Negative and Cognitive Symptoms

7. Pipeline Assessment

  • 7.1. Overview
  • 7.2. Early-Stage Pipeline Assessment
  • 7.3. Novel Therapeutic Approaches
    • 7.3.1. Negative Symptoms
    • 7.3.2. Cognitive Symptoms
  • 7.4. Long-Acting Drug Delivery
  • 7.5. Technology Trends Analysis
  • 7.6. Key Drugs in Clinical Development

8. EVP-6124

  • 8.1. Overview
  • 8.2. Efficacy
  • 8.3. Safety
    • 8.3.1. Dosing and Formulation
    • 8.3.2. Potential Clinical Positioning
    • 8.3.3. Potential Commercial Positioning
    • 8.3.4. Pricing and Reimbursement
  • 8.4. SWOT Analysis
  • 8.5. Forecast

9. Appendix

  • 9.1. Bibliography
  • 9.2. Abbreviations
  • 9.3. Methodology
  • 9.4. Forecasting Methodology
    • 9.4.1. Diagnosis and Treatment Rates
    • 9.4.2. Adherence Rates
    • 9.4.3. General Pricing Assumptions
    • 9.4.4. Generic Erosion
    • 9.4.5. Pricing of Pipeline Agents
  • 9.5. Key Opinion Leaders
  • 9.6. About the Authors
    • 9.6.1. Author
    • 9.6.2. Reviewers
    • 9.6.3. Global Head of Healthcare
  • 9.7. About GlobalData
  • 9.8. Disclaimer

List of Tables

  • Table 1: Symptom Clusters of Schizophrenia
  • Table 2: Common Subjective Rating Scales Employed in Schizophrenia Diagnosis
  • Table 3: Development-Based Classification of Antipsychotic Drugs
  • Table 4: Receptor Binding Profiles of Atypical Antipsychotics
  • Table 5: Guidelines for the Treatment of Schizophrenia
  • Table 6: Leading Branded Treatments for Schizophrenia, 2013
  • Table 7: Strategic Competitor Assessment of the Marketed Products in Schizophrenia, 2014
  • Table 8: Unmet Needs - Current Level of Attainment
  • Table 9: Clinical Unmet Needs - Gap Analysis, 2013
  • Table 10: Technological Trends Analytic Framework in the Schizophrenia Pipeline, 2014
  • Table 11: Pipeline Candidates in Development for Schizophrenia, 2014
  • Table 12: Comparison of Novel Therapeutic Classes in Development for Schizophrenia, 2013
  • Table 13: Product Profile - EVP-6124
  • Table 14: EVP-6124 SWOT Analysis, 2014
  • Table 15: Global Sales Forecast ($m) for EVP-6124, 2012-2022

List of Figures

  • Figure 1: Schizophrenia - Pipeline Drugs by Target, 2014
  • Figure 2: Competitive Assessment of Late-Stage Pipeline Agents in Schizophrenia, 2012-2022
Back to Top